Eliquis (apixaban) is a blood thinner used to treat and prevent blood clots in several specific conditions. It’s FDA-approved for five purposes: reducing stroke risk in people with atrial fibrillation, treating deep vein thrombosis (DVT), treating pulmonary embolism (PE), preventing DVT and PE from coming back, and preventing blood clots after hip or knee replacement surgery.
Stroke Prevention in Atrial Fibrillation
The most common reason people take Eliquis is to lower stroke risk caused by atrial fibrillation, a condition where the heart beats irregularly and allows blood to pool and form clots. If one of those clots travels to the brain, it causes a stroke. Oral anticoagulants like Eliquis can prevent up to two-thirds of strokes in people with atrial fibrillation.
In a large study of adults with short, symptomless bouts of irregular heart rhythm, those taking apixaban were 37% less likely to have a stroke or blood clot compared to those taking daily aspirin. The benefit was even more pronounced for severe events: fatal or disabling strokes dropped by 51%. Eliquis is specifically approved for “nonvalvular” atrial fibrillation, meaning it’s not intended for people whose irregular heartbeat is caused by a mechanical heart valve or certain valve conditions.
Treating DVT and Pulmonary Embolism
Deep vein thrombosis is a blood clot that forms in a deep vein, usually in the leg. A pulmonary embolism happens when a clot breaks free and travels to the lungs, which can be life-threatening. Eliquis treats both conditions by blocking a specific clotting factor in the blood, preventing existing clots from growing while the body gradually dissolves them.
Treatment typically starts at a higher dose for the first seven days, then drops to a lower maintenance dose. Your doctor may also prescribe a continued lower dose after the initial treatment period to prevent these clots from returning, which is the drug’s fourth approved use.
Preventing Clots After Joint Replacement
Hip and knee replacement surgeries carry a significant risk of blood clots forming in the legs during recovery, when you’re less mobile than usual. Eliquis is approved to prevent this. The treatment duration differs depending on the surgery: 35 days after hip replacement and 12 days after knee replacement. This reflects the longer period of reduced mobility and higher clot risk that comes with hip surgery compared to knee surgery.
How It Compares to Warfarin
Eliquis belongs to a class of newer blood thinners that have largely replaced warfarin (Coumadin) for many patients. The practical differences are significant. A study published in JACC: Advances comparing matched groups of over 3,500 patients on each drug found that major bleeding was less common with apixaban. Emergency room visits, hospitalizations for bleeding, and mortality rates were all higher with warfarin.
The day-to-day experience is also simpler. Warfarin requires regular blood tests to check clotting levels, and its effectiveness changes based on how much vitamin K you eat, meaning leafy greens like spinach and kale need to be consumed in consistent amounts. Eliquis has no interactions with vitamin K and no food restrictions. It doesn’t require routine blood monitoring either, which means fewer lab visits.
Dose Adjustments Based on Your Profile
For atrial fibrillation, some people take a reduced dose. The lower dose applies when at least two of the following three criteria are met: you’re 80 years or older, you weigh 132 pounds (60 kg) or less, or your kidney function is reduced beyond a certain threshold. Meeting just one of those criteria isn’t enough to trigger the dose change for atrial fibrillation.
Interestingly, the rules are different for blood clot treatment. When Eliquis is used for DVT or pulmonary embolism, no dose adjustment is recommended for kidney problems, age, or weight. This applies even to patients with end-stage kidney disease or those on dialysis. The distinction matters because the drug behaves differently depending on what it’s treating, and the clinical trials that established safe dosing were designed separately for each condition.
What Eliquis Does Not Treat
Eliquis is not a general-purpose blood thinner for all clotting situations. It’s not approved for people with mechanical heart valves, where different anticoagulants are needed. It doesn’t treat clots caused by certain blood disorders like antiphospholipid syndrome in most cases. And it’s not used for arterial clots that cause heart attacks, which involve a different clotting mechanism and require different medications like antiplatelet drugs.
If you’re taking Eliquis, one critical safety point: never stop it abruptly without medical guidance. Stopping suddenly can cause a rebound increase in clotting risk, particularly for people taking it for atrial fibrillation. Any changes to your regimen should be planned with your prescribing doctor.